Relay Therapeutics director proposes $2.73M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. reports a proposed sale by its director and officer Sanjiv Patel of 144,597 common shares, with an aggregate market value of $2,732,883.30 and an approximate sale date of July 7, 2026. The shares were acquired from the issuer as restricted stock units on February 10, 2025; the reported Rule 10b5-1 plan adoption or instruction date is October 30, 2025.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.